CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong
· Delayed Price · Currency is HKD 0.1360
+0.0030 (2.26%)
May 30, 2025, 3:59 PM HKT
CANbridge Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 85.1 | 102.87 | 78.97 | 31.16 | 12.03 | Upgrade
|
| Revenue Growth (YoY) | -17.27% | 30.26% | 153.43% | 158.98% | 719.06% | Upgrade
|
| Cost of Revenue | 30.8 | 38.71 | 30.08 | 12.39 | 5.15 | Upgrade
|
| Gross Profit | 54.3 | 64.16 | 48.89 | 18.78 | 6.88 | Upgrade
|
| Selling, General & Admin | 143.06 | 173.5 | 195.69 | 246.27 | 128.72 | Upgrade
|
| Research & Development | 251.76 | 257.21 | 311.17 | 427.66 | 109.64 | Upgrade
|
| Operating Expenses | 394.82 | 430.71 | 506.86 | 673.92 | 238.37 | Upgrade
|
| Operating Income | -340.52 | -366.55 | -457.97 | -655.15 | -231.49 | Upgrade
|
| Interest Expense | -8.58 | -8.95 | -6.86 | -3.08 | -3.79 | Upgrade
|
| Interest & Investment Income | 0.51 | 10.98 | 3.89 | 2.61 | 0.96 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.63 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -12.56 | -14.56 | -22.97 | 30.69 | -22.03 | Upgrade
|
| EBT Excluding Unusual Items | -361.15 | -379.08 | -483.91 | -624.3 | -256.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | 6.5 | - | 0.44 | 9.73 | - | Upgrade
|
| Asset Writedown | -87.99 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.03 | 0.24 | - | -462.44 | -589.7 | Upgrade
|
| Pretax Income | -442.62 | -378.84 | -483.48 | -1,077 | -846.04 | Upgrade
|
| Net Income | -442.62 | -378.84 | -483.48 | -1,077 | -846.04 | Upgrade
|
| Net Income to Common | -442.62 | -378.84 | -483.48 | -1,077 | -846.04 | Upgrade
|
| Shares Outstanding (Basic) | 425 | 424 | 424 | 94 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 425 | 424 | 424 | 94 | 69 | Upgrade
|
| Shares Change (YoY) | 0.11% | 0.04% | 350.13% | 37.39% | 0.12% | Upgrade
|
| EPS (Basic) | -1.04 | -0.89 | -1.14 | -11.43 | -12.33 | Upgrade
|
| EPS (Diluted) | -1.04 | -0.89 | -1.14 | -11.43 | -12.33 | Upgrade
|
| Free Cash Flow | -122.5 | -283.38 | -296.18 | -592.16 | -154.22 | Upgrade
|
| Free Cash Flow Per Share | -0.29 | -0.67 | -0.70 | -6.28 | -2.25 | Upgrade
|
| Gross Margin | 63.81% | 62.37% | 61.91% | 60.26% | 57.16% | Upgrade
|
| Operating Margin | -400.12% | -356.32% | -579.91% | -2102.46% | -1923.94% | Upgrade
|
| Profit Margin | -520.10% | -368.26% | -612.21% | -3456.26% | -7031.61% | Upgrade
|
| Free Cash Flow Margin | -143.94% | -275.47% | -375.04% | -1900.31% | -1281.74% | Upgrade
|
| EBITDA | -326.8 | -354.72 | -448.84 | -646.11 | -217.13 | Upgrade
|
| D&A For EBITDA | 13.72 | 11.82 | 9.13 | 9.04 | 14.36 | Upgrade
|
| EBIT | -340.52 | -366.55 | -457.97 | -655.15 | -231.49 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.